Secondary Logo

Journal Logo

Management of pseudohypoparathyroidism

Germain-Lee, Emily L.

doi: 10.1097/MOP.0000000000000783
ENDOCRINOLOGY AND METABOLISM: Edited by Sally Radovick
Open

Purpose of review This review is timely given the 2018 publication of the first international Consensus Statement for the diagnosis and management of pseudohypoparathyroidism (PHP) and related disorders. The purpose of this review is to provide the knowledge needed to recognize and manage PHP1A, pseudopseudohypoparathyroidism (PPHP) and PHP1B – the most common of the subtypes – with an overview of the entire spectrum and to provide a concise summary of management for clinical use. This review will draw from recent literature as well as personal experience in evaluating hundreds of children and adults with PHP.

Recent findings Progress is continually being made in understanding the mechanisms underlying the PHP spectrum. Every year, through clinical and laboratory studies, the phenotypes are elucidated in more detail, as are clinical issues such as short stature, brachydactyly, subcutaneous ossifications, cognitive/behavioural impairments, obesity and metabolic disturbances. Headed by a European PHP consortium, experts worldwide published the first international Consensus that provides detailed guidance in a systematic manner and will lead to exponential progress in understanding and managing these disorders.

Summary As more knowledge is gained from clinical and laboratory investigations, the mechanisms underlying the abnormalities associated with PHP are being uncovered as are improvements in management.

Department of Pediatrics, Division of Pediatric Endocrinology and Diabetes, Center for Rare Bone Disorders and Albright Center, University of Connecticut School of Medicine, Connecticut Children's Medical Center, Farmington, Connecticut, USA

Correspondence to Emily L. Germain-Lee, MD, Department of Pediatrics, Division of Pediatric Endocrinology and Diabetes, Center for Rare Bone Disorders and Albright Center, University of Connecticut School of Medicine, Connecticut Children's Medical Center, 505 Farmington Avenue, 2nd floor, Farmington, CT 06032, USA. Tel: +1 860 837 6719; fax: +1 860 837 6617; e-mail: germainlee@uchc.eduoregermain@connecticutchildrens.org

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0

Back to Top | Article Outline

INTRODUCTION

In 1942, Fuller Albright et al. [1] described a disorder characterized by end-organ resistance to parathyroid hormone (PTH) resulting in increased serum PTH levels, hypocalcaemia and hyperphosphatemia. The patients lacked the appropriate response to administration of PTH and had blunted urinary cAMP and phosphate excretion. The condition was named ‘pseudohypoparathyroidism’ (PHP) given that the PTH was elevated in the face of low calcium and high phosphorous levels [1]. These patients had specific somatic and developmental abnormalities such as a round facies with a ‘short, thickset figure’, heterotopic subcutaneous ossifications (SCOs), brachydactyly and cognitive impairment [1] (for review, [2,3]). This was later to be termed PHP type 1A (PHP1A). Approximately a decade later, Albright et al. [4] also identified a patient who had many of these same physical features but normal calcium, phosphorous and PTH levels as well as a normal phosphaturic response to PTH; this was named pseudopseudohypoparathyroidism (PPHP). The physical phenotype for both PHP1A and PPHP was termed Albright hereditary osteodystrophy (AHO).

AHO is a disorder caused by heterozygous inactivating mutations affecting exons 1–13 of GNAS, the gene encoding the α-chain of the stimulatory G protein, Gαs, which couples receptors for many hormones and neurotransmitters to activate adenylyl cyclase. GNAS is a complex locus [2,3] that encodes not only Gαs, with mutations causing AHO found in every exon [5], but also alternative transcripts through the use of alternative first exons that splice onto exons 2–13. The locus is controlled by genomic imprinting such that transcription from one parental allele is suppressed, often only partially. This imprinting is regulated through differentially methylated regions that are in the promoter regions for each exon (except exon 1 of GNAS needed for Gαs) (for review, [2,3,6,7]).

Patients with PHP1A have GNAS mutations on the maternally inherited allele and manifest resistance to multiple Gs protein coupled hormones [e.g. PTH, thyroid-stimulating hormone (TSH), luteinizing hormone (LH), follicle-stimulating hormone (FSH), growth hormone-releasing hormone (GHRH)] due to paternal imprinting of Gαs transcripts in specific tissues. These patients often have severe obesity, especially early-onset obesity. Patients with PPHP have GNAS mutations on the paternally inherited allele and have the AHO phenotype alone without hormonal resistance or the severe obesity. The identification of the difference in the obesity phenotype between PHP1A and PPHP raised the possibility that paternal imprinting in the hypothalamus may be the cause [8], given that the melanocortin 4 receptor (MC4R) is Gs-coupled, and this difference in phenotype was recently found to be due to imprinting in the dorsomedial hypothalamus, specifically the MC4R-expressing cells, based on extensive work on mouse models [9,10▪▪]. Thus, women affected with AHO have children with PHP1A affected by hormonal resistance and obesity, whereas men with AHO have children with PPHP without hormonal resistance and obesity [2,3,8,11].

Although the phenotype of a patient with AHO can be explained by the parental mode of transmission of the GNAS mutant allele, spontaneous mutations can also occur. In addition, abnormalities in imprinting due to mutations that affect methylation patterns typically cause a condition termed PHP1B (described below). PHP1C is also within this group of disorders but difficult to prove, as it presents in the same manner as PHP1A; it is due to mutations that impair receptor coupling activity of Gαs but not its basal activity.

Other conditions in the PHP spectrum of disorders are described in Table 1 including progressive osseous heteroplasia (POH) and the very rare PHP1A/POH combination [12,13]. When patients have a similar phenotype to PHP1A but do not have a mutation in GNAS, other related disorders need to be considered. The acrodysostosis syndromes have similarities to AHO but a more severe skeletal phenotype including striking midface/nasal hypoplasia; these syndromes can also involve resistance to multiple G protein coupled hormones. The genes involved in these disorders (Table 1) are downstream from GNAS in the cAMP pathway. Thus, all of the PHP and related disorders represent a spectrum with many similarities, all within this one pathway [14].

Table 1

Table 1

PHP is rare, and the prevalence is not truly known (estimate for Denmark: 1.1 per 100 000, 2016) [15]; however, the prevalence may be closer to 1 : 20 000 in the United States (unpublished). PPHP is especially likely to be more common than realized, as patients with this disorder often go unrecognized. In 2016, the European consortium for PHP proposed a methodological approach to classification based on ‘inactivating PTH/PTHrP signaling disorders’ in order to base the disorders on underlying mechanisms rather than phenotype [16]. This led to the European consortium for PHP to assemble experts from around the world to restructure characterization based on molecular causes and to develop the first international Consensus Statement on the diagnosis and management of PHP and related disorders. Published in 2018, this Consensus is a true milestone for the field [17▪▪].

The goal of this brief review is to provide the background to understand the most common PHP disorders within the framework of recent advances, as well as their management. A condensed summary of the pertinent details necessary for management of PHP1A, PPHP and PHP1B has been formulated into Table 2 to serve as an easy-to-use tool for clinical care. To understand the reasons behind the management detailed in Table 2, the basis of the similarities and differences between these disorders is explained in this review. For the most comprehensive set of guidelines for management of PHP and related disorders, the 2018 international Consensus Statement is recommended.

Table 2

Table 2

Table 2

Table 2

Table 2

Table 2

Box 1

Box 1

Back to Top | Article Outline

PSEUDOHYPOPARATHYROIDISM TYPE 1A AND PSEUDOPSEUDOHYPOPARATHYROIDISM

In tissues in which imprinting of GNAS does not play a prominent role, the phenotypic consequences of heterozygous loss of GNAS can be similar between the disorders, whereas in tissues in which imprinting does play a significant role, the clinical phenotypes can be very different depending on the parent-of-origin of the mutant GNAS allele.

Back to Top | Article Outline

SIMILAR PHENOTYPES FOR PSEUDOHYPOPARATHYROIDISM TYPE 1A AND PSEUDOPSEUDOHYPOPARATHYROIDISM: CLINICAL IMPLICATIONS

As denoted by its name, AHO is an osteodystrophy. Classically, there is brachydactyly due to shortening of the metacarpals and metatarsals most often involving metacarpals/metatarsals III, IV and V, although any can be involved, as well as the distal phalanx of the thumb, which is often broad and short (Fig. 1a–d). These features are often a key to diagnosis, particularly for patients with PPHP who may have no other signs. The most frequent presentation for PPHP occurs when a mother brings her child with PHP1A to clinic and is then noticed to have physical features of AHO that were not previously considered medically significant. The proposed mechanism of the brachydactyly is ineffective PTHrP receptor signal transduction resulting in accelerated differentiation of chondrocytes [18–20]. The brachydactyly is usually not apparent in infancy but evolves over time and is variable even among family members. Another important manifestation of AHO is Archibald's sign: when making a fist, there is absence of one or more knuckles (Fig. 1e). All of these hand/foot abnormalities can lead to problems with fine and gross motor activities [2] as well as carpal tunnel syndrome [21] and other orthopaedic issues [2,22].

FIGURE 1

FIGURE 1

Adult short stature occurs in both PHP1A and PPHP and is partly due to early closure of the epiphyses of the long bones secondary to premature chondrocyte differentiation. This typically begins near the start of adolescence (ages 9–13 years), at which time there is rapid advancement in the bone age and lack of a pubertal growth spurt [2,6,23–25]. However, during most of childhood, children are often NOT short. Therefore, short stature in childhood should not be used as one of the diagnostic criteria. Unfortunately, many children are diagnosed late due to this misconception (personal observation). All adults have shortened final heights if no interventions are taken. On occasion, the advanced bone age in children is misconstrued as early-onset puberty, and patients are inadvertently started on GnRH agonists (personal observation). Because of the shortened hand bones, the hand/wrist bone age is often advanced [26,27] (even as early as 2 years of age, personal observation) and is ahead of the knee bone age, which is usually more accurate, although adult height cannot be predicted [2,23,25]. The biallelic expression of GNAS in bone and chondrocytes likely explains the similar phenotype of short stature and brachydactyly in both PHP1A and PPHP [18,19,28]. Growth hormone (GH) deficiency due to GHRH resistance is frequent [23,24] in PHP1A (next section) and also compromises height.

Another striking feature of PHP1A and PPHP is the development of SCOs that can be painful and impair activities of daily living (Fig. 2) [2,29]. These ossifications are unique to disorders involving mutations in GNAS and are often a key to diagnosis. SCO can range greatly in size and number and can occur spontaneously as early as birth; they frequently occur in areas of trauma/pressure, such as the heel, belt area or bridge of the nose from glasses. When in isolation, the condition is termed osteoma cutis, but this can also be the first sign of a more severe PHP disorder (Table 1). In a recent investigation of 67 AHO patients monitored for development of these SCO over a 16-year time span [30▪], about 70% of AHO patients were found to have SCO, with the same frequency seen in PHP1A and PPHP. Males are more affected than females, and a greater severity of SCO is found in patients with frameshift and nonsense mutations. Severity within families is similar, and SCO tend to worsen with age. There is no definitive treatment, and removal can cause regrowth that is worse [30▪].

FIGURE 2

FIGURE 2

Back to Top | Article Outline

DIFFERENCES BETWEEN PSEUDOHYPOPARATHYROIDISM TYPE 1A AND PSEUDOPSEUDOHYPOPARATHYROIDISM

The differences in phenotype between PHP1A and PPHP reflect differences in the expression of the maternal versus paternal alleles in different tissues. This was shown through extensive investigation of murine models with heterozygous disruption of Gnas exon 1 or exon 2 (homozygous is lethal) as well as human studies showing evidence of tissue-specific silencing of Gαs expression from the paternal allele. The imprinting is partial in most tissues, with preferential expression of the maternal allele in the renal cortex, thyroid, gonad and pituitary, thereby causing the hormonal resistances to PTH, TSH, LH, FSH, and GHRH, respectively; there is biallelic expression in other tissues such as skin, renal medulla, heart, adipocytes, chondrocytes and bone [18,23,24,28,31–39]. As previously mentioned, dorsomedial hypothalamic imprinting has recently been shown to be the basis of the severe obesity that is present in PHP1A but not in PPHP [9,10▪▪,40].

Back to Top | Article Outline

Hormonal resistance

Parathyroid hormone resistance

PTH resistance is the hallmark of PHP1A. It is typically not present at birth and develops later in childhood with an elevation in PTH usually followed by hyperphosphatemia and then hypocalcaemia, although some patients do not develop hypocalcaemia until later (for review, [2]). This emphasizes the need to screen for maternal GNAS mutations in the presence of SCOs alone, even in the absence of PTH resistance [41▪]. Occasionally, patients present with seizures, especially those previously undiagnosed. For diagnostic purposes, it is important to document that 25-hydroxyvitamin D levels are normal at the time of the PTH measurement, as secondary hyperparathyroidism can contribute to PTH elevations; magnesium levels also need to be verified as normal. Hypercalciuria is rarely observed in PHP1A because imprinting occurs only in proximal renal tubules and not in the ascending limb or the collecting ducts [2,34,42]. There is reduced excretion of phosphate and reduced 1,25-dihydroxyvitamin D mediated uptake of calcium, whereas calcium reabsorption in the distal parts of the kidney remains unaffected. The risk of nephrocalcinosis is low, although it can rarely occur; renal ultrasounds are indicated only if there is hypercalciuria (personal observation, [43▪]). In addition, dual-energy x-ray absorptiometry (DXA) should only be performed for a clinical indication, as PHP1A patients typically have normal to increased bone mineral density [44].

Back to Top | Article Outline

Thyroid-stimulating hormone resistance

TSH resistance is very commonly associated with PTH resistance with resulting normal or low thyroxine levels. The TSH resistance is mild due to partial imprinting in the thyroid [35–37] and presents without a goitre. It is often detected in infants during the newborn screen, being mistaken for congenital hypothyroidism. An infant with a ‘positive’ congenital hypothyroidism screen and ossifications should immediately trigger screening for PHP1A. In general, if an infant or child with hypothyroidism is being successfully treated with levothyroxine but continues to have an excessive increase in weight, the possible diagnosis of PHP1A should be entertained.

Back to Top | Article Outline

Luteinizing hormone/follicle-stimulating hormone resistance

Patients with PHP1A have evidence of hypogonadism and incomplete sexual maturation [45], most likely due to partial imprinting in gonadal tissue [36], but pubertal onset occurs at the usual time. Amenorrhea or oligomenorrhea is common in women [45,46], and oestrogen therapy is often needed, being aware of the potential risk of DVT formation (personal observation). Elevated LH/FSH levels would be expected in the face of gonadotropin resistance, but this is not consistently observed [45]. Although it is difficult to assess the true reproductive fitness of PHP1A patients due to their cognitive and social issues (see below), studies in Gnas exon 1 knockout mice have revealed significantly reduced fertility in females with maternally derived disrupted alleles (and minimally in those with paternally derived disrupted alleles) [31].

Back to Top | Article Outline

Growth hormone-releasing hormone resistance

A markedly increased prevalence of GH deficiency occurs in PHP1A (about two-thirds of patients) due to resistance to GHRH secondary to partial imprinting in the pituitary [2,23,24,38]. Treatment with recombinant GH results in an increased growth velocity [23,25,47,48] in PHP1A. A long-standing clinical trial of GH treatment in GH-deficient children with PHP1A through final height [49] is showing promising preliminary results with a significant increase in final adult height compared with untreated GH-deficient PHP1A adults [48,unpublished observation]. Testing for GH status, as well as recombinant GH treatment for GH-deficient PHP1A patients, is part of the 2018 Consensus guidelines [17▪▪]. All PHP1A patients with moderate to severe obesity and/or snoring were screened with ENT examinations and sleep studies prior to treatment in the aforementioned GH trial, as GH treatment carries the potential risk of worsening obstructive sleep apnoea (OSA), such as from tonsillar/adenoidal hypertrophy [48,49]. This is important to include in standard of care treatment of GH-deficient PHP1A patients with recombinant GH (personal experience).

Although GH deficiency contributes to short stature in about two-thirds of patients with PHP1A, the premature fusion of the epiphyses has a large impact on the final adult height, as previously discussed. A study of GH-sufficient PHP1A children treated with GH is still underway in order to determine the effect on final adult height of increasing growth velocity maximally prior to the premature epiphyseal fusion [49]. Overall, it has been noticed that GH treatment does not increase ossification growth [30▪] or have atypical side effects [48,49].

Back to Top | Article Outline

Other resistances

Calcitonin and glucagon resistances have also been reported [7,39] but are not as common as other hormonal resistances. ACTH resistance is typically not seen [7,24].

Back to Top | Article Outline

Obesity

Obesity and hypothalamic imprinting

Classically, the obesity in AHO had been described as occurring similarly in both PHP1A and PPHP. However, approximately a decade ago, severe obesity was found to be a feature of PHP1A only and not PPHP [8]. This was the first indication that hypothalamic imprinting may be involved. Early-onset obesity was also significant. Morbid obesity without evidence of hyperphagia was identified [2,50], and it was discovered that the cause of rapid weight gain in childhood was not hyperphagia but rather a decrease in resting energy expenditure (REE) [51,52,53▪]. In adults with PHP1A, there are higher rates of type 2 diabetes and reduced insulin sensitivity compared with obese controls [54]. However, it was recently reported that children with PHP1A are at a high risk for dysglycaemia without reduced insulin sensitivity and have lower HgbA1c levels than controls. Interestingly, these children seem to have an increased sucrose preference as well [53▪].

The obesity phenotype had also been demonstrated in Gnas exon 1 knockout mouse models [31,32]. Elegant studies of tissue-specific knockout models by Chen et al. [40] since that time have shown that the obesity is due to hypothalamic paternal imprinting of Gαs in the central nervous system (CNS). They recently identified this as being specific to the MC4R-expressing cells of the dorsomedial hypothalamus and demonstrated that Gαs is necessary for control of energy balance, thermogenesis and peripheral glucose metabolism with no impact on food intake, thereby correlating with the human phenotype [9,10▪▪].

Back to Top | Article Outline

Obesity and sleep apnoea

The prevalence of sleep apnoea in PHP1A (including both OSA and central apnoea) was found to occur at a 4.4-fold greater relative risk than similarly obese children in a retrospective study, which was out of proportion to the obesity alone [55]. A recent prospective study revealed that significant OSA occurred in 60% of children with PHP1A and seemed amplified possibly due to their craniofacial issues, along with an increased prevalence of hypotonia and asthma [22,56▪].

Back to Top | Article Outline

Cognitive, behavioral and developmental abnormalities in pseudohypoparathyroidism type 1A and pseudopseudohypoparathyroidism

In 1986, Farfel and Friedman [57] reported that reductions in Gαs levels were associated with cognitive impairment, with 47–75% of patients with PHP1A having intellectual disability. Twenty years later, the estimate was nearly 79% of affected individuals [42,58]. The cognitive deficits range from minimal learning disabilities to severe impairment [2,42,59,60,61▪,62] often requiring early interventions and therapies [61▪,62]. In a study of PHP1A children, lower intelligence quotient (IQ) scores (full scale, nonverbal, verbal) and impaired behavioural, adaptive, attention and executive function scores were identified, along with stronger nonverbal abilities than verbal [49,62,unpublished observations]. In a recent study with comparisons to siblings and age-matched controls, 16 PHP1A children were found to have significantly lower IQ scores (25% composite IQ <70) for both verbal and nonverbal IQ. There were also executive and adaptive function deficits and ADHD [61▪].

Patients with PPHP have overall higher social functioning as adults than those with PHP1A (unpublished). Interestingly, studies in mice demonstrated that females with a maternally inherited mutation neglected their young, resulting in nearly 80% mortality among pups before weaning, in contrast with those with a paternally inherited mutation, which showed normal mothering behaviour. This suggests the possibility of abnormal behaviour due to paternal imprinting in the CNS [31]. Cognitive testing in a single kindred with AHO implicated imprinting, with PHP1A family members being more affected than those with PPHP [58], although this study was limited by the small number of patients and by the use of a single measure for cognitive function. Abnormalities in olfaction and hearing have also been reported in PHP1A and are not present in PPHP [63–66], suggesting the involvement of GNAS imprinting in other parts of the CNS.

Overall, the cognitive and behavioural issues can lead to difficulties with independent living in adulthood, and a tremendous amount of support and advocacy from the medical team is needed for the patients and their families long-term (personal experience and [67▪]).

Back to Top | Article Outline

PSEUDOHYPOPARATHYROIDISM TYPE 1B

PHP1B is characterized by PTH resistance without clear AHO signs or other hormonal resistances, although these patients have occasional mild brachydactyly and mild TSH resistance [42]. Recently, early-onset obesity was defined as an important feature of PHP1B by Grüters-Kieslich et al.[68▪], and in a small kindred of three PHP1B children, decreased REE and dysglycaemia were recently reported, similar to PHP1A [53▪]. These findings further emphasize the overlap in the PHP disorders. Ossifications are very rare in PHP1B (none seen by author), and cognitive issues are not typically observed. Recently, bone mineral density studies of 48 patients with PHP1B stressed that PTH needs to be maintained at appropriate levels when treating to avoid adverse effects on bone [69▪].

PHP1B is typically due to methylation defects at one or more of the GNAS promoter regions (see Table 1; [6,70,71]). Fifteen to 20% of PHP1B cases are autosomal dominant caused by a recurrent 3-kb deletion removing a genomic region upstream of GNAS that contains STX16. However, most cases are sporadic [71]. Methylation testing as well as targeted testing for the STX16 deletion are available for diagnostic confirmation of PHP1B.

Back to Top | Article Outline

DIFFERENCES IN BIRTH WEIGHTS AND GROWTH PARAMETERS BETWEEN PSEUDOHYPOPARATHYROIDISM TYPE 1A, PSEUDOPSEUDOHYPOPARATHYROIDISM AND PSEUDOHYPOPARATHYROIDISM TYPE 1B

A recently published investigation of a large group of PHP patients by Hanna et al.[72▪] involved analysis of growth data from an international collaboration that reviewed 242 PHP1A, 64 PPHP and 220 PHP1B patients, all molecularly confirmed. This is an informative study, although one caveat is that the TSH, GHRH and medication status of these patients were unknown, which could impact these data. Patterns were found in PHP1A that revealed birth weights slightly below the mean with a striking increase in BMI by 1 year of age; this weight gain continued into childhood. There was absence of a pubertal growth spurt and poor final adult height in spite of an often normal height when younger, as described by others previously [2,3,23,25]. BMI z-scores were increased in adulthood, consistent with prior findings in smaller studies [2,8], with women much heavier than men. The PPHP infants were born small for gestational age (SGA) as previously reported [73]; they then had moderate catch-up growth but later had no pubertal growth spurt with ultimate short adult heights. PHP1B patients had macrosomia at birth and an increased BMI and growth velocity in childhood; they then had a shortened or absent pubertal growth spurt but normal final heights. They were overweight/obese as adults but not as severe as PHP1A. This study emphasizes the unique growth patterns within the PHP disorders and that the early-onset obesity of PHP1A and PHP1B can persist through adulthood, suggesting that dietary control should start very early in life and be maintained.

Back to Top | Article Outline

CONCLUSION

This review provides the background necessary to understand PHP1A, PPHP and PHP1B within the framework of recent advances and management of the conditions. A summary table is provided as a practical management tool for use in clinic. In addition, the spectrum of other PHP disorders is introduced. As we learn more about PHP, it is clear that there is an overlap between the various types. These disorders are complex and require comprehensive management. Being an advocate for these patients is vital to improving their quality of life. The 2018 international Consensus Statement is a major stride in improving patient care.

Back to Top | Article Outline

Acknowledgements

The author wishes to thank Alexzandrea Buscarello, B.S. (Clinical Research Assistant II) for her help in preparation of the references, figures and formatting of this review. The author's research that is mentioned within this review was supported by U.S. Food and Drug Administration Office of Orphan Products Development Grants R01 FD-R-002568 and R01 FD-R-003409 (both to E.L.G-L.) and National Institutes of Health Grant R21 HD078864 (to E.L.G-L.).

Back to Top | Article Outline

Financial support and sponsorship

None.

Back to Top | Article Outline

Conflicts of interest

There are no conflicts of interest.

Back to Top | Article Outline

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

  • ▪ of special interest
  • ▪▪ of outstanding interest
Back to Top | Article Outline

REFERENCES

1. Albright F, Burnett C, Smith P. Pseudohypoparathyroidism: an example of Seabright-Bantam syndrome. Endocrinology 1942; 30:922–932.
2. Plagge A, Kelsey G, Germain-Lee EL. Physiological functions of the imprinted Gnas locus and its protein variants Galpha(s) and XLalpha(s) in human and mouse. J Endocrinol 2008; 196:193–214.
3. Levine MA. An update on the clinical and molecular characteristics of pseudohypoparathyroidism. Curr Opin Endocrinol Diabetes Obes 2012; 19:443–451.
4. Albright F, Forbes AP, Henneman PH. Pseudo-pseudohypoparathyroidism. Trans Assoc Am Physicians 1952; 65:337–350.
5. Lemos MC, Thakker RV. GNAS mutations in pseudohypoparathyroidism type 1a and related disorders. Hum Mutat 2015; 36:11–19.
6. Linglart A, Levine MA, Jüppner H. Pseudohypoparathyroidism. Endocrinol Metab Clin North Am 2018; 47:865–888.
7. Levine MA, Germain-Lee E, Jan de Beur S. Genetic basis for resistance to parathyroid hormone. Horm Res 2003; 60 (Suppl 3):87–95.
8. Long DN, McGuire S, Levine MA, et al. Body mass index differences in pseudohypoparathyroidism type 1a versus pseudopseudohypoparathyroidism may implicate paternal imprinting of Gα s in the development of human obesity. J Clin Endocrinol Metab 2007; 92:1073–1079.
9. Chen M, Shrestha YB, Podyma B, et al. Gsα deficiency in the dorsomedial hypothalamus underlies obesity associated with Gsα mutations. J Clin Invest 2017; 127:500–510.
10▪▪. Podyma B, Sun H, Wilson EA, et al. The stimulatory G protein Gsα is required in melanocortin 4 receptor-expressing cells for normal energy balance, thermogenesis, and glucose metabolism. J Biol Chem 2018; 293:10993–11005.

The impressive work from this investigation in Gαs knockout mice demonstrated that Gαs imprinting in the melanocortin 4 receptor-expressing cells in the dorsomedial hypothalamus provides an explanation for the obesity in PHP1A; this represents the culmination of years of critical work by several of these investigators.

11. Davies SJ, Hughes HE. Imprinting in Albright's hereditary osteodystrophy. J Med Genet 1993; 30:101–103.
12. Eddy MC, Jan De Beur SM, Yandow SM, et al. Deficiency of the alpha-subunit of the stimulatory G protein and severe extraskeletal ossification. J Bone Miner Res 2000; 15:2074–2083.
13. Lin MH, Numbenjapon N, Germain-Lee EL, Pitukcheewanont P. Progressive osseous heteroplasia, as an isolated entity or overlapping with Albright hereditary osteodystrophy. J Pediatr Endocrinol Metab 2015; 28 (7–8):911–918.
14. Mantovani G, Elli FM. Multiple hormone resistance and alterations of G-protein-coupled receptors signaling. Best Pract Res Clin Endocrinol Metab 2018; 32:141–154.
15. Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. Pseudohypoparathyroidism: epidemiology, mortality and risk of complications. Clin Endocrinol (Oxf) 2016; 84:904–911.
16. Thiele S, Mantovani G, Barlier A, et al. From pseudohypoparathyroidism to inactivating PTH/PTHrP signalling disorder (iPPSD), a novel classification proposed by the EuroPHP network. Eur J Endocrinol 2016; 175:1–17.
17▪▪. Mantovani G, Bastepe M, Monk D, et al. Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement. Nat Rev Endocrinol 2018; 14:476–500.

This is the first international Consensus Statement ever written for the diagnosis and management of PHP and its spectrum of disorders, which will guide patients and practitioners for years to come and which resulted from experts worldwide meeting together (assembled by the European consortium for PHP).

18. Sakamoto A, Chen M, Kobayashi T, et al. Chondrocyte-specific knockout of the G protein G(s)alpha leads to epiphyseal and growth plate abnormalities and ectopic chondrocyte formation. J Bone Miner Res 2005; 20:663–671.
19. Bastepe M, Weinstein LS, Ogata N, et al. Stimulatory G protein directly regulates hypertrophic differentiation of growth plate cartilage in vivo. Proc Natl Acad Sci U S A 2004; 101:14794–14799.
20. Kobayashi T, Chung U-I, Schipani E, et al. PTHrP and Indian hedgehog control differentiation of growth plate chondrocytes at multiple steps. Development 2002; 129:2977–2986.
21. Joseph AW, Shoemaker AH, Germain-Lee EL. Increased prevalence of carpal tunnel syndrome in Albright hereditary osteodystrophy. J Clin Endocrinol Metab 2011; 96:2065–2073.
22. Shoemaker AH, Jüppner H. Nonclassic features of pseudohypoparathyroidism type 1A. Curr Opin Endocrinol Diabetes Obes 2017; 24:33–38.
23. Germain-Lee EL, Groman J, Crane JL, et al. Growth hormone deficiency in pseudohypoparathyroidism type 1a: another manifestation of multihormone resistance. J Clin Endocrinol Metab 2003; 88:4059–4069.
24. Mantovani G, Maghnie M, Weber G, et al. Growth hormone-releasing hormone resistance in pseudohypoparathyroidism type Ia: new evidence for imprinting of the Gs alpha gene. J Clin Endocrinol Metab 2003; 88:4070–4074.
25. Germain-Lee EL. Short stature, obesity, and growth hormone deficiency in pseudohypoparathyroidism type 1a. Pediatr Endocrinol Rev 2006; 3 (Suppl 2):318–327.
26. Steinbach HL, Young DA. The roentgen appearance of pseudohypoparathyroidism (PH) and pseudo-pseudohypoparathyroidism (PPH). Differentiation from other syndromes associated with short metacarpals, metatarsals, and phalanges. Am J Roentgenol Radium Ther Nucl Med 1966; 97:49–66.
27. Fitch N, Opitz JM, Herrmann J. Albright's hereditary osteodystrophy: a review. Am J Med Genet 1982; 11:11–29.
28. Mantovani G, Bondioni S, Locatelli M, et al. Biallelic expression of the Gsalpha gene in human bone and adipose tissue. J Clin Endocrinol Metab 2004; 89:6316–6319.
29. Huso DL, Edie S, Levine MA, et al. Heterotopic ossifications in a mouse model of Albright hereditary osteodystrophy. PLoS One 2011; 6:e21755.
30▪. Salemi P, Skalamera Olson JM, Dickson LE, Germain-Lee EL. Ossifications in Albright hereditary osteodystrophy: role of genotype, inheritance, sex, age, hormonal status, and BMI. J Clin Endocrinol Metab 2018; 103:158–168.

This study examined a large group of patients with Albright hereditary osteodystrophy over a span of 16 years and found that about 70% of both PHP1A and PPHP patients had SCOs, which were more extensive in those with frameshift and nonsense mutations and which were more pronounced in males than in females.

31. Germain-Lee EL, Schwindinger W, Crane JL, et al. A mouse model of Albright hereditary osteodystrophy generated by targeted disruption of exon 1 of the Gnas gene. Endocrinology 2005; 146:4697–4709.
32. Chen M, Gavrilova O, Liu J, et al. Alternative Gnas gene products have opposite effects on glucose and lipid metabolism. Proc Natl Acad Sci U S A 2005; 102:7386–7391.
33. Yu S, Yu D, Lee E, et al. Variable and tissue-specific hormone resistance in heterotrimeric Gs protein alpha-subunit (Gsalpha) knockout mice is due to tissue-specific imprinting of the gsalpha gene. Proc Natl Acad Sci U S A 1998; 95:8715–8720.
34. Weinstein LS, Yu S, Ecelbarger CA. Variable imprinting of the heterotrimeric G protein G(s) alpha-subunit within different segments of the nephron. Am J Physiol Renal Physiol 2000; 278:F507–514.
35. Germain-Lee EL, Ding CL, Deng Z, et al. Paternal imprinting of Galpha(s) in the human thyroid as the basis of TSH resistance in pseudohypoparathyroidism type 1a. Biochem Biophys Res Commun 2002; 296:67–72.
36. Mantovani G, Ballare E, Giammona E, et al. The gsalpha gene: predominant maternal origin of transcription in human thyroid gland and gonads. J Clin Endocrinol Metab 2002; 87:4736–4740.
37. Liu J, Erlichman B, Weinstein LS. The stimulatory G protein alpha-subunit Gs alpha is imprinted in human thyroid glands: implications for thyroid function in pseudohypoparathyroidism types 1A and 1B. J Clin Endocrinol Metab 2003; 88:4336–4341.
38. Hayward BE, Barlier A, Korbonits M, et al. Imprinting of the G(s)alpha gene GNAS1 in the pathogenesis of acromegaly. J Clin Invest 2001; 107:R31–R36.
39. Levine MA, Eil C, Downs RW, Spiegel AM. Deficient guanine nucleotide regulatory unit activity in cultured fibroblast membranes from patients with pseudohypoparathyroidism type I. A cause of impaired synthesis of 3’,5’-cyclic AMP by intact and broken cells. J Clin Invest 1983; 72:316–324.
40. Chen M, Wang J, Dickerson KE, et al. Central nervous system imprinting of the G protein G(s)alpha and its role in metabolic regulation. Cell Metab 2009; 9:548–555.
41▪. Usardi A, Mamoune A, Nattes E, et al. Progressive development of PTH resistance in patients with inactivating mutations on the maternal allele of GNAS. J Clin Endocrinol Metab 2017; 102:1844–1850.

This study emphasizes the need to screen for maternal GNAS mutations in the presence of SCOs or positive family history even in the absence of PTH resistance, as the PTH elevations can develop late.

42. Haldeman-Englert CR, Hurst AC, Levine MA. Disorders of GNAS inactivation. GeneReviews [Internet]. University of Washington, Seattle; 2017 [cited 2019 May 16]; [about 53 p.]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459117/.
43▪. Hansen DW, Nebesio TD, DiMeglio LA, et al. Prevalence of nephrocalcinosis in pseudohypoparathyroidism: is screening necessary? J Pediatr 2018; 199:263–266.

Hypercalciuria is not typical in PHP1A, and this study further emphasizes that renal ultrasounds are indicated only when hypercalciuria is present.

44. Long DN, Levine MA, Germain-Lee EL. Bone mineral density in pseudohypoparathyroidism type 1a. J Clin Endocrinol Metab 2010; 95:4465–4475.
45. Namnoum AB, Merriam GR, Moses AM, Levine MA. Reproductive dysfunction in women with Albright's hereditary osteodystrophy. J Clin Endocrinol Metab 1998; 83:824–829.
46. Wolfsdorf JI, Rosenfield RL, Fang VS, et al. Partial gonadotrophin-resistance in pseudohypoparathyroidism. Acta Endocrinol 1978; 88:321–328.
47. Mantovani G, Ferrante E, Giavoli C, et al. Recombinant human GH replacement therapy in children with pseudohypoparathyroidism type Ia: first study on the effect on growth. J Clin Endocrinol Metab 2010; 95:5011–5017.
48. Germain-Lee EL. Albright hereditary osteodystrophy & growth hormone. Lecture presented at Endocrine Society Meeting; 2014; Chicago, IL. Available from https://endo.confex.com/endo/2014endo/webprogram/Session3489.html.
49. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29- Identifier NCT00209235, Albright hereditary osteodystrophy: natural history, growth, and cognitive/behavioral assessments; 2005 Sept 3 [cited 2019 May 16]; [about 6 screens]. Available from: http://clinicaltrials.gov/ct/show/NCT00209235.
50. Dekelbab BH, Aughton DJ, Levine MA. Pseudohypoparathyroidism type 1A and morbid obesity in infancy. Endocr Pract 2009; 15:249–253.
51. Shoemaker AH, Lomenick JP, Saville BR, et al. Energy expenditure in obese children with pseudohypoparathyroidism type 1a. Int J Obes 2013; 37:1147–1153.
52. Roizen JD, Danzig J, Groleau V, et al. Resting energy expenditure is decreased in pseudohypoparathyroidism type 1A. J Clin Endocrinol Metab 2016; 101:880–888.
53▪. Perez KM, Curley KL, Slaughter JC, Shoemaker AH. Glucose homeostasis and energy balance in children with pseudohypoparathyroidism. J Clin Endocrinol Metab 2018; 103:4265–4274.

These results support the investigators’ prior studies showing that decreased REE, not severe hyperphagia, is one of the main causes of abnormal weight gain in PHP and is the first study to show that children with PHP are at an increased risk for dysglycaemia without having reduced insulin sensitivity.

54. Muniyappa R, Warren MA, Zhao X, et al. Reduced insulin sensitivity in adults with pseudohypoparathyroidism type 1a. J Clin Endocrinol Metab 2013; 98:E1796–E1801.
55. Landreth H, Malow BA, Shoemaker AH. Increased prevalence of sleep apnea in children with pseudohypoparathyroidism type 1a. HRP 2015; 84:1–5.
56▪. Curley KL, Kahanda S, Perez KM, et al. Obstructive sleep apnea and otolaryngologic manifestations in children with pseudohypoparathyroidism. Horm Res Paediatr 2018; 89:178–183.

Screening for OSA should be considered in all patients with PHP due to the high prevalence of OSA (compared with a control group with a similar degree of obesity), and PHP patients seem to have a greater risk of otitis media and tonsillar/adenoidal hypertrophy.

57. Farfel Z, Friedman E. Mental deficiency in pseudohypoparathyroidism type I is associated with Ns-protein deficiency. Ann Intern Med 1986; 105:197–199.
58. Mouallem M, Shaharabany M, Weintrob N, et al. Cognitive impairment is prevalent in pseudohypoparathyroidism type Ia, but not in pseudopseudohypoparathyroidism: possible cerebral imprinting of Gsalpha. Clin Endocrinol (Oxf) 2008; 68:233–239.
59. Marguet C, Mallet E, Basuyau JP, et al. Clinical and biological heterogeneity in pseudohypoparathyroidism syndrome. Results of a multicenter study. Horm Res 1997; 48:120–130.
60. Rutter MM, Smith EP. Pseudohypoparathyroidism type Ia: late presentation with intact mental development. J Bone Miner Res 1998; 13:1208–1209.
61▪. Perez KM, Lee EB, Kahanda S, et al. Cognitive and behavioral phenotype of children with pseudohypoparathyroidism type 1A. Am J Med Genet A 2018; 176:283–289.

This study of 16 PHP1A children added comparisons to siblings and age-matched controls when investigating their cognitive and behavioural function and found significant impairments.

62. Ramos VL, Mahone EM, Germain-Lee EL. Neuropsychological functioning in Albright hereditary osteodystrophy: a case series (abstract). J Int Neuropsychol Soc 2014; 20 (Suppl S1):16.
63. Doty RL, Fernandez AD, Levine MA, et al. Olfactory dysfunction in type I pseudohypoparathyroidism: dissociation from Gs alpha protein deficiency. J Clin Endocrinol Metab 1997; 82:247–250.
64. Henkin RI. Impairment of olfaction and of the tastes of sour and bitter in pseudohypoparathyroidism. J Clin Endocrinol Metab 1968; 28:624–628.
65. Koch T, Lehnhardt E, Böttinger H, et al. Sensorineural hearing loss owing to deficient G proteins in patients with pseudohypoparathyroidism: results of a multicentre study. Eur J Clin Invest 1990; 20:416–421.
66. Weinstock RS, Wright HN, Spiegel AM, et al. Olfactory dysfunction in humans with deficient guanine nucleotide-binding protein. Nature 1986; 322:635–636.
67▪. Linglart A, Mantovani G, Garin I, et al. The importance of networking in pseudohypoparathyroidism: EuroPHP Network and Patient Support Associations. Pediatr Endocrinol Rev 2017; 15 (Suppl 1):92–97.

This study emphasizes the tremendous importance of advocacy and support for PHP patients and their families.

68▪. Grüters-Kieslich A, Reyes M, Sharma A, et al. Early-onset obesity: unrecognized first evidence for GNAS mutations and methylation changes. J Clin Endocrinol Metab 2017; 102:2670–2677.

This study demonstrated that obesity can be the first clinical evidence for PHP1B in an infant or young child and highlights the need to consider testing for methylation defects of GNAS in the setting of early-onset obesity.

69▪. Chu X, Zhu Y, Wang O, et al. Bone mineral density and its serial changes are associated with PTH levels in pseudohypoparathyroidism type 1B patients. J Bone Miner Res 2018; 33:743–752.

The importance of maintaining PTH levels within the normal range to maintain bone health is demonstrated in this largest study of bone mineral density in PHP1B.

70. Hayward BE, Moran V, Strain L, Bonthron DT. Bidirectional imprinting of a single gene: GNAS1 encodes maternally, paternally, and biallelically derived proteins. Proc Natl Acad Sci U S A 1998; 95:15475–15480.
71. Tafaj O, Jüppner H. Pseudohypoparathyroidism: one gene, several syndromes. J Endocrinol Invest 2017; 40:347–356.
72▪. Hanna P, Grybek V, Perez de Nanclares G, et al. Genetic and epigenetic defects at the GNAS locus lead to distinct patterns of skeletal growth but similar early-onset obesity. J Bone Miner Res 2018; 33:1480–1488.

This study investigated the largest cohort of patients with PHP1A, PPHP and PHP1B for growth parameters and emphasizes that childhood height does not predict adult stature and that maternal mutations or methylation defects of GNAS (i.e. PHP1A and PHP1B) can lead to significant early-onset obesity that can persist throughout adulthood.

73. Richard N, Molin A, Coudray N, et al. Paternal GNAS mutations lead to severe intrauterine growth retardation (IUGR) and provide evidence for a role of XLαs in fetal development. J Clin Endocrinol Metab 2013; 98:E1549–E1556.
Keywords:

Albright hereditary osteodystrophy; GNAS; pseudohypoparathyroidism; pseudopseudohypoparathyroidism

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.